Regencell Bioscience Holdings Ltd (RGC) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

Medium Risk

Moderate dilution risk

Last updated: October 31, 2025

Risk Assessment Details

Potential Dilution: 0.0% of current shares

Recent Dilution: 3700.0% (2 years)

Historical Dilution Factor: significant recent dilution

Outstanding Shares

490M

Potential Supply

Additional shares possible

Splits

None

Past 2 years

Summary

RGC currently has 494M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 3700.0% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding
Oct 31, 2025	20-F filing \| 494.5M shares outstanding	490M
Oct 25, 2024	20-F filing \| 13.0M shares outstanding	13M
Oct 27, 2023	20-F filing \| 13.0M shares outstanding	13M
Oct 31, 2022	20-F filing \| 12.8M shares outstanding	13M
Oct 29, 2021	20-F filing \| 10.0M shares outstanding	10M
Mar 22, 2021	F-1 filing: This is an F-1 filing for Regencell Bioscience Holdings Limited, an early-stage bioscience company focusing on TCM for neurocognitive disorders. The offering involves Ordinary Shares and the company intends to list on the Nasdaq Capital Market under the symbol "RGCB."	N/A

Back to RGC Details